98 Monitoring the Safety of Second Generation Antipsychotics in Children and Adolescents with Autism Spectrum Disorder

摘要

Approximately 17.5% of youth with autism spectrum disorder (ASD) are treated with second-generation antipsychotics (SGAs). While SGAs have been found to reduce irritability and associated behaviours in youth with ASD, a range of side effects has been reported. Therefore, careful monitoring of youth taking these medications is imperative. However, as the core and associated symptoms of ASD can make medical procedures challenging, monitoring the safety of SGAs may be particularly difficult in this population. To date, there has been little investigation of how closely physicians monitor SGA side effects in youth with ASD or the barriers that they face in doing so.